Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan\u2019s Leading Covid-19 Vaccine Produced by Adimmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eden Biologics\u2019 Leading Biosimilar Program Receives Phase 3 Approval in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Eden Biologics

    Menu

    Eden Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Eden Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eden Biologics’ Leading Biosimilar Program Receives Phase 3 Approval in Europe

              Details:

              EB-CLIN-1001-03 phase 3 clinical trial for the leading biosimilar program EB1001, a Denosumab biosimilar, for the future treatment of osteoporosis, giant cell tumors of bone, and other skeletal-related events from metastatic solid tumors.

              Lead Product(s): Denosumab

              Therapeutic Area: Musculoskeletal Product Name: EB1001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eden Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan’s Leading Covid-19 Vaccine Produced by Adimmune

              Details:

              Under the terms of the Master Service Agreement, JHL Biotech will support Adimmune Corporation to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.

              Lead Product(s): Covid-19 vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Adimmune

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eden Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar

              Details:

              The Three-Arm Study is randomized, double-blinded, parallel-grouped, and single-dosed and will compare the pharmacokinetic similarity of JHL1266 versus Prolia® sourced from the EU and the US in healthy human subjects.

              Lead Product(s): Denosumab

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eden Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Taiwan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar

              Details:

              JHL1266, a proposed biosimilar to denosumab, is a monoclonal antibody targeting RANKL and works by inhibiting the development of osteoclasts and then preventing break down of bones in the human body.

              Lead Product(s): Denosumab

              Therapeutic Area: Musculoskeletal Product Name: JHL1266

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY